BR112022007616A2 - Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763) - Google Patents
Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763)Info
- Publication number
- BR112022007616A2 BR112022007616A2 BR112022007616A BR112022007616A BR112022007616A2 BR 112022007616 A2 BR112022007616 A2 BR 112022007616A2 BR 112022007616 A BR112022007616 A BR 112022007616A BR 112022007616 A BR112022007616 A BR 112022007616A BR 112022007616 A2 BR112022007616 A2 BR 112022007616A2
- Authority
- BR
- Brazil
- Prior art keywords
- sickle cell
- cell disease
- vit
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924556P | 2019-10-22 | 2019-10-22 | |
| EP19000483 | 2019-10-22 | ||
| EP20163777 | 2020-03-17 | ||
| EP20176336 | 2020-05-25 | ||
| PCT/EP2020/079802 WO2021078889A1 (en) | 2019-10-22 | 2020-10-22 | Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007616A2 true BR112022007616A2 (pt) | 2022-07-12 |
Family
ID=73005635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007616A BR112022007616A2 (pt) | 2019-10-22 | 2020-10-22 | Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220274973A1 (https=) |
| EP (1) | EP4048262A1 (https=) |
| JP (1) | JP7594004B2 (https=) |
| KR (1) | KR20220086563A (https=) |
| CN (1) | CN114765955B (https=) |
| AU (1) | AU2020369137A1 (https=) |
| BR (1) | BR112022007616A2 (https=) |
| CA (1) | CA3154524A1 (https=) |
| IL (1) | IL291137A (https=) |
| MX (1) | MX2022004806A (https=) |
| WO (1) | WO2021078889A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025535398A (ja) | 2022-10-21 | 2025-10-24 | ビフォー （インターナショナル） エージー | 二環式フェロポーチン阻害剤 |
| EP4731218A1 (en) | 2023-06-26 | 2026-04-29 | Vifor (International) AG | Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh) |
| WO2026041650A1 (en) | 2024-08-20 | 2026-02-26 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of lupus nephritis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002416C (en) | 2015-10-23 | 2023-10-24 | Vifor (International) Ag | Benzimidazolyl derivatives for use as ferroportin inhibitors |
| US11191818B2 (en) * | 2016-08-04 | 2021-12-07 | Takeda Pharmaceutical Company Limited | Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome |
| JOP20180036A1 (ar) * | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| ES2934492T3 (es) | 2018-12-13 | 2023-02-22 | Global Blood Therapeutics Inc | Inhibidores de ferroportina y métodos de uso |
-
2020
- 2020-10-22 AU AU2020369137A patent/AU2020369137A1/en active Pending
- 2020-10-22 JP JP2022523485A patent/JP7594004B2/ja active Active
- 2020-10-22 EP EP20796575.7A patent/EP4048262A1/en active Pending
- 2020-10-22 MX MX2022004806A patent/MX2022004806A/es unknown
- 2020-10-22 BR BR112022007616A patent/BR112022007616A2/pt unknown
- 2020-10-22 US US17/636,575 patent/US20220274973A1/en not_active Abandoned
- 2020-10-22 CA CA3154524A patent/CA3154524A1/en active Pending
- 2020-10-22 CN CN202080074094.0A patent/CN114765955B/zh active Active
- 2020-10-22 WO PCT/EP2020/079802 patent/WO2021078889A1/en not_active Ceased
- 2020-10-22 KR KR1020227012237A patent/KR20220086563A/ko active Pending
-
2022
- 2022-03-06 IL IL291137A patent/IL291137A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023500060A (ja) | 2023-01-04 |
| CA3154524A1 (en) | 2021-04-21 |
| IL291137A (en) | 2022-05-01 |
| US20220274973A1 (en) | 2022-09-01 |
| JP7594004B2 (ja) | 2024-12-03 |
| WO2021078889A1 (en) | 2021-04-29 |
| KR20220086563A (ko) | 2022-06-23 |
| AU2020369137A1 (en) | 2022-04-07 |
| CN114765955B (zh) | 2025-06-24 |
| EP4048262A1 (en) | 2022-08-31 |
| MX2022004806A (es) | 2022-05-16 |
| CN114765955A (zh) | 2022-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007192A (es) | Inhibidores de prmt5. | |
| MX2022003984A (es) | Compuestos heterociclicos antivirales. | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| ECSP099376A (es) | Inhibidores de la actividad de la akt | |
| NI200700320A (es) | Inhibidores de la actividad akt | |
| BR112012010705A2 (pt) | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| MX2018011100A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| NI202100047A (es) | COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE alfa1-ANTITRIPSINA | |
| BR112022007616A2 (pt) | Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763) | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| UY38614A (es) | Derivados de benzodiazepinas como inhibidores del rsv | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| MX2024004216A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. | |
| BR112013008211A8 (pt) | Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| MX2022007174A (es) | Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |